LONDON--(BUSINESS WIRE)--Johnson & Johnson Innovation, London, today announces the formation of a network of partnering offices across UK life science clusters. The offices function as extensions of its London Innovation Centre to work with academics and entrepreneurs throughout the UK to identify early stage innovation and support the translation of research into new products for patients.
While the London Innovation Centre continues to be the primary hub for interactions with the academic and entrepreneurial community in the greater London area, these new partnering offices are part of a broader strategy to interact more directly with life science “hotspots” throughout the UK and Europe.
Johnson & Johnson Innovation is establishing partnering offices in the following locations that will function as a base for interactions throughout the regions:
- Babraham Research Campus for the wider Cambridge area
- University of Oxford Old Road Campus for the wider Oxford area
- The University of Manchester Innovation Centre (UMIC) for the North and Midlands
- Edinburgh BioQuarter for Scotland and Northern Ireland
- Life Sciences Hub Wales in Cardiff for Wales and the South West
Representatives from the Johnson & Johnson Innovation Centre in London will establish a regular presence in each of the partnering offices that are expected to be fully operational in early 2014.
"Establishing these partnering offices reflects our commitment to collaborative innovation and our belief that being close to the source of innovation drives our ability to create strong networks of people who can combine ideas, resources and technologies in a new way to tackle urgent unmet medical needs,” commented Patrick Verheyen, head of the Johnson & Johnson Innovation Centre, London.
“Opening these new partnering offices extends the approach we piloted with Stevenage Bioscience Catalyst (SBC) earlier this year,” commented Dr. Kurt Hertogs, Incubator Strategy Leader for the Johnson & Johnson Innovation, London. “Our continuing experience with SBC confirms this model as an effective way for our scientific teams to interact with innovators and entrepreneurs, and advance promising healthcare solutions. Given the number and diversity of research campuses, incubators, and life science parks throughout the UK and Europe, we believe the establishing of these regional partnering offices will enable us to reach out and more effectively collaborate with innovators across the UK and Europe.”
About Johnson & Johnson Innovation
The London Innovation Centre is part of Johnson & Johnson Innovation, a division of Johnson & Johnson Finance Limited. Johnson & Johnson Innovation focuses on accelerating early innovation and enhancing opportunities for collaboration and investment across Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies focused on early stage opportunities a one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and diagnostics and consumer companies of Johnson & Johnson. Johnson & Johnson Innovation includes local deal-making capabilities with the flexibility to adapt deal structures to match early-stage opportunities and establish novel collaborations that speed development of innovations to solve unmet needs in patients. For more information please visit: www.jnjinnovation.com.
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson Innovation, Johnson & Johnson Finance Limited and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of Johnson & Johnson Innovation, Johnson & Johnson Finance Limited or Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.)